Monopar Therapeutics Reports Q1 2026 Financials, Extends Cash Runway to End of 2027, ALXN1840 NDA Expected Mid-2026
MNPR has more than doubled off its 52-week low of $28.4.
Summary
Monopar Therapeutics reported Q1 2026 results, showing increased R&D spend and a cash runway through December 2027, with its lead candidate ALXN1840's NDA submission now targeted for mid-2026.
Key Events · Earnings and Guidance · MNPR
-
Strong Cash Position and Extended Runway
The company reported $137.5 million in cash, cash equivalents, and investments as of March 31, 2026, and estimates these funds will be sufficient to meet obligations through December 31, 2027.
-
Increased Research and Development Expenses
R&D expenses significantly increased to $3.49 million for Q1 2026, up from $1.64 million in Q1 2025, reflecting active advancement of its clinical programs.
-
ALXN1840 NDA Submission Timeline Update
The NDA submission for ALXN1840, its lead candidate for Wilson disease, is now expected in mid-2026, following continued dialogue with the FDA.
-
Ongoing Radiopharmaceutical Pipeline Progress
Monopar continues to advance its MNPR-101-Zr (Phase 1 imaging) and MNPR-101-Lu (Phase 1a therapeutic) clinical trials, with MNPR-101-Ac in late preclinical development.
Analysis · MNPR · Life Sciences
Monopar Therapeutics' latest quarterly report provides an updated financial snapshot and key pipeline developments. The company maintains a strong cash position, extending its operational runway through December 2027, which is crucial for a clinical-stage biotech. The increased R&D expenses reflect active development across its ALXN1840 and radiopharmaceutical programs. While the ALXN1840 NDA submission is now anticipated in mid-2026, indicating a slight delay, the ongoing positive clinical data and constructive dialogue with the FDA suggest continued progress towards regulatory approval.
At the time of this filing, MNPR was trading at $58.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $394.2M. The 52-week trading range was $28.40 to $105.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.